Pathogenesis and management of diabetic dyslipidemia.

about

Genetic linkage of hyperglycemia, body weight and serum amyloid-P in an intercross between C57BL/6 and C3H apolipoprotein E-deficient mice.Metformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trials

P2860

Q30440146-CE0C7D78-5590-4F56-98B6-24191E2DE18A Q37364089-ADD6ECC5-58B1-43F2-8B36-4350458D2B97

P2860

Pathogenesis and management of diabetic dyslipidemia.

Item

http://www.wikidata.org/entity/Q36168178

description

2003 nî lūn-bûn

@nan

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

2003年论文

@zh

2003年论文

@zh-cn

name

Pathogenesis and management of diabetic dyslipidemia.

@ast

Pathogenesis and management of diabetic dyslipidemia.

@en

type

Item

label

Pathogenesis and management of diabetic dyslipidemia.

@ast

Pathogenesis and management of diabetic dyslipidemia.

@en

prefLabel

Pathogenesis and management of diabetic dyslipidemia.

@ast

Pathogenesis and management of diabetic dyslipidemia.

@en

P1476

Pathogenesis and management of diabetic dyslipidemia.

@en

P2093

Ardon Rubinstein

http://www.w3.org/2001/XMLSchema#string

Elena Izkhakov

http://www.w3.org/2001/XMLSchema#string

Eyal Meltzer

http://www.w3.org/2001/XMLSchema#string

P2860

Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease

Mechanism of action of fibrates on lipid and lipoprotein metabolism

Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice.

Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23)

LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study.

Lipoprotein glycation and its metabolic consequences.

Recent progress in understanding apolipoprotein B.

When to start cholesterol-lowering therapy in patients with coronary heart disease. A statement for healthcare professionals from the American Heart Association Task Force on Risk Reduction.

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study.

Predictors of stroke in middle-aged patients with non-insulin-dependent diabetes.

P2888

00024677-200302040-00002

P304

231-245

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2165/00024677-200302040-00002

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2003-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1003715422

http://www.w3.org/2001/XMLSchema#string

P698

15966559

http://www.w3.org/2001/XMLSchema#string

P921

dyslipidemias

Pathogenesis and management of diabetic dyslipidemia.

about

P2860

P2860

Pathogenesis and management of diabetic dyslipidemia.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921